OncoMatch/Clinical Trials/NCT05413421

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Is NCT05413421 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for metastatic prostate cancer.

Phase 1RecruitingORIC PharmaceuticalsNCT05413421Data as of May 2026

Treatment: ORIC-944 · Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets · Apalutamide (Erleada™) 60 mg or 240 mg tablets · Darolutamide (Nubeqa®) 300 mg tablets · Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets — The purpose of this study is to establish the safety and preliminary antitumor activity of ORIC-944 as a single agent and in combinations with ARPIs in patients with metastatic prostate cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Disease stage

Metastatic disease required

Performance status

ECOG 0–1(Restricted strenuous activity)

Lab requirements

Blood counts

adequate organ function

Kidney function

adequate organ function

Liver function

adequate organ function

Adequate organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Rocky Mountain Cancer Center · Colorado Springs, Colorado
South Florida Oncology and Hematology · Plantation, Florida
Illinois Cancer Specialists · Arlington Heights, Illinois
Comprehensive Urologic Care · Lake Barrington, Illinois
First Urology · Jeffersonville, Indiana

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify